Pretreatment Serum C-Reactive Protein Levels Predict Benefit From Multimodality Treatment Including Radical Surgery in Malignant Pleural Mesothelioma
- 1 August 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Annals of Surgery
- Vol. 256 (2), 357-362
- https://doi.org/10.1097/sla.0b013e3182602af4
Abstract
To evaluate the prognostic and predictive relevance of pretreatment serum C-reactive protein (CRP) in malignant pleural mesothelioma (MPM) patients. MPM is a rare but aggressive disease with poor treatment outcome. Therapeutic decision is challenging, and predictive biomarkers for better treatment stratification are urgently needed. Clinical data, including survival and pretreatment CRP levels, were retrospectively collected from 115 patients with histologically proven MPM. Patients with any evidence for infectious disease were excluded. The association between CRP levels and survival was analyzed using Cox models adjusted for clinical and pathological factors. Median pretreatment CRP of all patients was 1.19 mg/dL (range: 0.00-22.62 mg/dL). Patients with elevated CRP levels (≥1 mg/dL; n = 62, 53.9%) had a significantly shorter overall survival compared with those with normal CRP (hazard ratio [HR] 2.81, 95% confidence interval [CI] 1.82-4.33; P < 0.001). In multivariate survival analyses, elevated CRP was confirmed as an independent prognostic factor in MPM (HR 2.07, 95% CI 1.23-3.46; P = 0.01). Most interestingly, we observed a significant interaction between CRP and treatment modality (P < 0.001). Among patients with normal CRP levels, radical tumor resection within multimodality therapy was associated with distinctly prolonged overall survival when compared with treatment protocols without surgery (HR 7.26, 95% CI 3.40-15.49; P < 0.001). In contrast among patients with elevated CRP, no survival benefit was achieved by radical surgery within multimodality approaches (HR 0.911, 95% CI 0.53-1.58; P = 0.74). Our results suggest that multimodality regimens including radical resection increase survival selectively in MPM patients with normal pretreatment serum CRP levels.Keywords
This publication has 53 references indexed in Scilit:
- Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV MelanomaClinical Cancer Research, 2011
- Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive proteinBritish Journal of Cancer, 2010
- Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancerBritish Journal of Cancer, 2010
- Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesotheliomaEuropean Respiratory Journal, 2009
- Elevated Biomarkers of Inflammation Are Associated With Reduced Survival Among Breast Cancer PatientsJournal of Clinical Oncology, 2009
- Four-Gene Expression Ratio Test for Survival in Patients Undergoing Surgery for MesotheliomaJNCI Journal of the National Cancer Institute, 2009
- Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancerBritish Journal of Cancer, 2007
- Biology and management of malignant pleural mesotheliomaEuropean Journal of Cancer, 2006
- C-Reactive Protein Levels, Variation in the C-Reactive Protein Gene, and Cancer Risk: The Rotterdam StudyJournal of Clinical Oncology, 2006
- Acute-Phase Proteins and Other Systemic Responses to InflammationThe New England Journal of Medicine, 1999